SLC5A2 and type 2 diabetes mellitus: The key finding emerging from the study was that patients with T2DM who received SGLT-2 inhibitors and had concomitant CAD were associated with a numerically higher incidence of genital infections as compared to those without CAD patients, but the difference was not statistically significant (p=0.712).